They work by copying a hormone your body makes naturally
GLP-1 secretion is increased by inflammatory stimuli in an IL-6dependent manner, leading to hyperinsulinemia and blood glucose lowering
We hypothesize that ACSL4 sensitizes AT II cells to Bet v 1-induced ferroptosis
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function
We're excited to make these solutions more accessible than ever through our partnership with Sprouts
Jun 2014;58(4):335-340
